Senzime to Showcase Expanded TetraGraph Capabilities with Launch of TetraAnalytics at Euroanaesthesia 2026

Rhea-AI Summary

Senzime (OTCQX:SNZZF) launched TetraAnalytics, a cloud-based data analytics platform that extends the TetraGraph neuromuscular monitoring system. The platform automates data analysis, tracks protocol and guideline alignment, uses the Train-of-Four Quality Indicator (TQi), and supports advanced visualization and remote analytics for perioperative care improvement.

Senzime will showcase TetraAnalytics, the next-generation TetraGraph system and the new TetraSens EMG sensor at Euroanaesthesia 2026 in Rotterdam and sponsor a lunch symposium on neuromuscular monitoring advances.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UPPSALA, SE / ACCESS Newswire / June 5, 2026 / Senzime AB (STO:SEZI)(OTCQX:SNZZF), a global leader in precision-based patient monitoring, today announced the launch of TetraAnalytics^™, a new data analytics platform designed to expand the value of the TetraGraph^® system. TetraAnalytics generates advanced clinical and operational insights, helping hospitals align with clinical guidelines, increase utilization and further leverage the benefits of quantitative neuromuscular monitoring.

TetraAnalytics complements the TetraGraph ecosystem by providing hospitals and anesthesia departments with a new cloud-based platform to automate data analysis, track alignment with protocols and guidelines, support best-practice monitoring conditions using the proprietary Train-of-Four Quality Indicator (TQi), and drive continuous improvement across perioperative care.

The platform also enables advanced data visualization and remote analytics capabilities, helping institutions strengthen implementation of quantitative neuromuscular monitoring and accelerate adoption of evidence-based care.

"TetraAnalytics marks another important step forward in our mission to make precision-based neuromuscular monitoring the standard of care," said Philip Siberg, CEO of Senzime. "With TetraGraph, we brought accurate, user-friendly EMG-based monitoring to operating rooms around the world. TetraAnalytics builds on that foundation by enabling hospitals to further analyze TetraGraph data, track utilization and protocol adherence, and support ongoing improvements in patient safety."

Senzime will showcase TetraAnalytics, the next-generation TetraGraph system and the recently launched new TetraSens EMG sensor in booth 3.36 at Euroanaesthesia 2026, the annual congress of the European Society of Anaesthesiology and Intensive Care, taking place June 6-8, 2026, in Rotterdam.

During Euroanaesthesia 2026, Senzime is also sponsoring a lunch symposium titled "From Acceleration to Precision: How New Technologies and Guidelines Are Advancing Neuromuscular Monitoring" on Saturday, June 6, from 12:00-13:00 in Room Rotterdam B. The session will be moderated by Sorin J. Brull, MD, FCARCSI (Hon), and feature Oscar Diaz, MD, PhD; Aaron Persinger, MD; Nicola Disma, MD, PhD; and Debra Faulk, MD. The discussion will explore how new comparative data, real-world clinical experience, and evolving guidelines are shaping the next standard of neuromuscular care in adults and children.

About TetraAnalytics
TetraAnalytics is Senzime's cloud-based data analytics platform for neuromuscular monitoring. The platform is designed to help healthcare institutions securely review TetraGraph case data, uncover clinical and operational insights, support best-practice monitoring conditions using the proprietary Train-of-Four Quality Indicator (TQi), and evaluate compliance with institutional protocols and clinical guidelines. The platform supports data-driven improvement in neuromuscular block management and expands the value of the TetraGraph ecosystem from real-time monitoring to longitudinal clinical insight. More information is available at senzime.com/tetraanalytics.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

About Senzime

Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph^® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.

Attachments

Senzime to Showcase Expanded TetraGraph Capabilities with Launch of TetraAnalytics at Euroanaesthesia 2026

SOURCE: Senzime

View the original press release on ACCESS Newswire

FAQ

What is Senzime's TetraAnalytics platform launched in June 2026 for SNZZF investors?

TetraAnalytics is a cloud-based analytics platform that expands the capabilities of Senzime’s TetraGraph monitoring system. According to Senzime, it automates data analysis, tracks protocol and guideline alignment, applies the Train-of-Four Quality Indicator, and supports continuous perioperative care improvement and evidence-based neuromuscular monitoring.

How does TetraAnalytics enhance the TetraGraph neuromuscular monitoring system for hospitals?

TetraAnalytics enhances TetraGraph by turning monitoring data into clinical and operational insights for hospitals and anesthesia departments. According to Senzime, it enables automated analytics, advanced data visualization, remote analytics, utilization tracking, and protocol adherence monitoring, helping institutions strengthen quantitative neuromuscular monitoring and patient safety initiatives.

What will Senzime (OTCQX:SNZZF) present at Euroanaesthesia 2026 in Rotterdam?

Senzime will present TetraAnalytics, the next-generation TetraGraph system and the new TetraSens EMG sensor at Euroanaesthesia 2026. According to Senzime, these offerings will be showcased in booth 3.36 during the congress held June 6-8, 2026, in Rotterdam, Netherlands.

What is the Train-of-Four Quality Indicator (TQi) used in Senzime’s TetraAnalytics platform?

The Train-of-Four Quality Indicator (TQi) is a proprietary measure supporting best-practice neuromuscular monitoring conditions. According to Senzime, TetraAnalytics uses TQi to help hospitals assess monitoring quality, align with clinical guidelines, and drive continuous improvement in perioperative neuromuscular care and patient outcomes.

What is the topic and schedule of Senzime’s Euroanaesthesia 2026 lunch symposium?

Senzime’s lunch symposium is titled “From Acceleration to Precision: How New Technologies and Guidelines Are Advancing Neuromuscular Monitoring.” According to Senzime, it will occur Saturday, June 6, 2026, from 12:00-13:00 in Room Rotterdam B during Euroanaesthesia 2026.

Who are the key speakers at Senzime’s neuromuscular monitoring symposium at Euroanaesthesia 2026?

The symposium will be moderated by Sorin J. Brull, MD, FCARCSI (Hon). According to Senzime, speakers include Oscar Diaz, MD, PhD; Aaron Persinger, MD; Nicola Disma, MD, PhD; and Debra Faulk, MD, discussing technology, guidelines and real-world neuromuscular monitoring data.